Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Elotuzumab, Isatuximab, and Selinexor-Based Regimens in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Noemi Puig, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Patricia Cost, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, José María Sanchez-Pina, Serena Rocchi

Blood (2023) 142 (Supplement 1): 6910.

https://doi.org/10.1182/blood-2023-182164

Published: 2023

Journal Articles

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Blood (2023) 142 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2023-179922

Published: 2023

Journal Articles

High Humoral Response after Anti-Sars-Cov-2 mRNA-Based Vaccines in Patients with Active Multiple Myeloma (MM) and Relationship with Disease Status/Line of Therapy

Katia Mancuso, Elena Zamagni, Vincenza Solli, Liliana Gabrielli, Lucia Pantani, Serena Rocchi, Ilaria Rizzello, Paola Tacchetti, Alessio Fusco, Gabriella De Cicco, Margherita Ursi, Marco Talarico, Emanuele Favero, Giuliana Nepoti, Barbara Ruffini, Carolina Terragna, Tiziana Lazzarotto, Pier Luigi Zinzani, Michele Cavo

Blood (2021) 138 (Supplement 1): 4732.

https://doi.org/10.1182/blood-2021-150266

Published: 2021

Journal Articles

A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 Patients Collected By European Myeloma Network within Harmony Big Data Platform

Blood (2020) 136 (Supplement 1): 34–37.

https://doi.org/10.1182/blood-2020-137021

Published: 2020

Journal Articles

Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1778.

https://doi.org/10.1182/blood-2019-127799

Published: 2019

Journal Articles

Serum Free Light Chain Assay As an Additional Tool for Defining Response and Progressive Disease in Immunoglobulin Secretory Multiple Myeloma

Paola Tacchetti, Serena Rocchi, Luca Dozza, Elena Zamagni, MD, Isola Caratozzolo, MD, Ilaria Rizzello, Alessio Fusco, MD, Gabriella De Cicco, MD, Lucia Pantani, MD, Katia Mancuso, Carolina Terragna, Nicoletta Testoni, Pier Luigi Luigi Zinzani, MD, Michele Cavo

Blood (2019) 134 (Supplement_1): 1796.

https://doi.org/10.1182/blood-2019-128715

Published: 2019

Journal Articles

A Maturation Index Defines Newly Diagnosed Multiple Myeloma Patients with Advanced Immunophenotypic and Molecular Differentiation Profiles Associated with Poor Prognosis

Blood (2019) 134 (Supplement_1): 1797.

https://doi.org/10.1182/blood-2019-129975

Published: 2019

Journal Articles

The Pliancy of Plasma Cell Differentiation Status Conceals a Gradient of Chromosomal Instability in Newly Diagnosed Multiple Myeloma Patients

Blood (2017) 130 (Supplement 1): 1769.

https://doi.org/10.1182/blood.V130.Suppl_1.1769.1769

Published: 2017

Journal Articles

High-Risk Cytogenetics in Newly Diagnosed Multiple Myeloma: Prognostic Relevance of Co-Segregations and Analysis of the Role of Double Versus Single Autotransplantation

Blood (2017) 130 (Supplement 1): 394.

https://doi.org/10.1182/blood.V130.Suppl_1.394.394

Published: 2017

Journal Articles

An Amplicon-Targeted Ultra-Deep Sequencing Approach Reveals the Presence at the Onset of Multiple Myeloma and the Selection over Time of TP53 Sub-Clonal Variants, Which Adversely Influence Patients' Overall Survival

Carolina Terragna, PhD, Marina Martello, PhD, Mauro Procacci, Flavio Mignone, Annalisa Pezzi, PhD, Barbara Santacroce, Lucia Pantani, MD, Igor Saggese, Torsten Haferlach, Elena Zamagni, Enrica Borsi, PhD, Paola Tacchetti, MD, Beatrice A Zannetti, MD, Serena Rocchi, MD, Katia Mancuso, MD, Flores A Dico, Giovanni Martinelli, MD PhD, Michele Cavo

Blood (2015) 126 (23): 24.

https://doi.org/10.1182/blood.V126.23.24.24

Published: 2015

Journal Articles

Long-Term Clinical Outcomes of Allogeneic Stem Cell Transplantation in Multiple Myeloma

Elena Zamagni, Giuseppe Bandini, Annalisa Pezzi, PhD, Paola Tacchetti, Ilaria Rizzello, Lucia Pantani, Mario Arpinati, MD PhD, Beatrice A Zannetti, MD, Serena Rocchi, Mariarosaria Sessa, Annamaria Brioli, Katia Mancuso, Carolina Terragna, PhD, Nicoletta Testoni, Francesca Bonifazi, Michele Cavo, MD

Blood (2015) 126 (23): 1968.

https://doi.org/10.1182/blood.V126.23.1968.1968

Published: 2015

Journal Articles

High-Throughput Molecular Profiling of Multiple Myeloma (MM) Clonotypic CD19+ B Cells Highlights Pathways Potentially Involved in the Disease Endurance

Marina Martello, PhD, Angela Flores Dico, Daniel Remondini, PhD, Giovanni Martinelli, MD, Enrica Borsi, PhD, Barbara Santacroce, Lucia Pantani, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Anna Beatrice Zannetti, MD, Katia Mancuso, MD, Serena Rocchi, MD, Annalisa Pezzi, Statistician, Nicoletta Testoni, PhD, Giulia Marzocchi, PhD, Gaia Ameli, Michele Cavo, MD, Carolina Terragna, PhD

Blood (2014) 124 (21): 2054.

https://doi.org/10.1182/blood.V124.21.2054.2054

Published: 2014

Journal Articles

Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

Annamaria Brioli, MD, Annalisa Pezzi, Statistician, Daniele Derudas, MD, Maria Concetta Petti, MD, Beatrice Anna Zannetti, MD, Felicetto Ferrara, MD, Serena Rocchi, MD, Francesco Nobile, MD, Anna Baraldi, MD, Pellegrino Musto, MD, Francesco Lanza, MD, Katia Mancuso, MD, Letizia Canepa, MD, Lucio Catalano, MD, Antonio Lazzaro, MD, Graziella Pinotti, MD, Mario Boccadoro, MD, Michele Cavo, MD

Blood (2014) 124 (21): 1182.

https://doi.org/10.1182/blood.V124.21.1182.1182

Published: 2014

Journal Articles

A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM)

Blood (2014) 124 (21): 3400.

https://doi.org/10.1182/blood.V124.21.3400.3400

Published: 2014

Journal Articles

Prognostic Impact Of Serum Free Light Chain (sFLC) Assay In Newly Diagnosed Multiple Myeloma (MM) Treated With Bortezomib

Paola Tacchetti, MD, Serena Rocchi, MD, Annalisa Pezzi, Elena Zamagni, MD, Lucia Pantani, MD, Beatrice Anna Zannetti, MD, Katia Mancuso, MD, Annamaria Brioli, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2013) 122 (21): 1859.

https://doi.org/10.1182/blood.V122.21.1859.1859

Published: 2013

Journal Articles

PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression During The Follow-Up Of The Disease: A Single Centre Experience On 282 Patients

Elena Zamagni, MD, Cristina Nanni, MD, Annalisa Pezzi, Statistics, Katia Mancuso, Paola Tacchetti, MD, Lucia Pantani, MD, Beatrice Anna Zannetti, MD, Annamaria Brioli, MD, Serena Rocchi, MD, Giulia Marzocchi, PhD, Nicoletta Testoni, BS, Carolina Terragna, PhD, Giovanni Martinelli, MD, Stefano Fanti, MD, Michele Cavo, MD

Blood (2013) 122 (21): 1936.

https://doi.org/10.1182/blood.V122.21.1936.1936

Published: 2013

Journal Articles

Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4

Carolina Terragna, PhD, Marina Martello, Enrica Borsi, PhD, Lucia Pantani, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Brioli Annamaria, MD, Beatrice Anna Zannetti, MD, Flores Dico, Nicoletta Testoni, BS, Giulia Marzocchi, PhD, Katia Mancuso, MD, Serena Rocchi, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2013) 122 (21): 1855.

https://doi.org/10.1182/blood.V122.21.1855.1855

Published: 2013

Journal Articles

Superior Outcomes With Bortezomib Or Thalidomide Incorporated Into Autologous Stem Cell Transplantation (ASCT) Versus Novel Agent-Based Treatments For Elderly Patients With Newly Diagnosed Multiple Myeloma (MM): A Case-Match Comparison

Blood (2013) 122 (21): 3344.

https://doi.org/10.1182/blood.V122.21.3344.3344

Published: 2013

NARROW

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Elotuzumab, Isatuximab, and Selinexor-Based Regimens in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

High Humoral Response after Anti-Sars-Cov-2 mRNA-Based Vaccines in Patients with Active Multiple Myeloma (MM) and Relationship with Disease Status/Line of Therapy

A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 Patients Collected By European Myeloma Network within Harmony Big Data Platform

Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma

Serum Free Light Chain Assay As an Additional Tool for Defining Response and Progressive Disease in Immunoglobulin Secretory Multiple Myeloma

A Maturation Index Defines Newly Diagnosed Multiple Myeloma Patients with Advanced Immunophenotypic and Molecular Differentiation Profiles Associated with Poor Prognosis

The Pliancy of Plasma Cell Differentiation Status Conceals a Gradient of Chromosomal Instability in Newly Diagnosed Multiple Myeloma Patients

High-Risk Cytogenetics in Newly Diagnosed Multiple Myeloma: Prognostic Relevance of Co-Segregations and Analysis of the Role of Double Versus Single Autotransplantation

An Amplicon-Targeted Ultra-Deep Sequencing Approach Reveals the Presence at the Onset of Multiple Myeloma and the Selection over Time of TP53 Sub-Clonal Variants, Which Adversely Influence Patients' Overall Survival

Long-Term Clinical Outcomes of Allogeneic Stem Cell Transplantation in Multiple Myeloma

High-Throughput Molecular Profiling of Multiple Myeloma (MM) Clonotypic CD19+ B Cells Highlights Pathways Potentially Involved in the Disease Endurance

Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM)

Prognostic Impact Of Serum Free Light Chain (sFLC) Assay In Newly Diagnosed Multiple Myeloma (MM) Treated With Bortezomib

PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression During The Follow-Up Of The Disease: A Single Centre Experience On 282 Patients

Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4

Superior Outcomes With Bortezomib Or Thalidomide Incorporated Into Autologous Stem Cell Transplantation (ASCT) Versus Novel Agent-Based Treatments For Elderly Patients With Newly Diagnosed Multiple Myeloma (MM): A Case-Match Comparison

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only